3 antibody; and anti glypican 3 antibody that has a plasma half life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti glypican 3 antibody, and {HEAD ~ a method} of preparing the anti glypican 3 antibody and producing {TAIL ~ a pharmaceutical composition} comprising the anti glypican 3 antibody as an active ingredient 
3 antibody ; and anti glypican 3 antibody that has a plasma half life that has been modulated by amino acid residue modification , a pharmaceutical composition comprising as an active ingredient the anti glypican 3 antibody , and { HEAD ~ a method } of preparing the anti glypican 3 antibody and producing { TAIL ~ a pharmaceutical composition } comprising the anti glypican 3 antibody as an active ingredient
OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH HEAD HEAD HEAD HEAD HEAD HEAD REL OTH OTH OTH OTH OTH OTH OTH REL TAIL TAIL TAIL TAIL TAIL TAIL TAIL OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH